KR20200019261A - 비효율적 적혈구생성 치료를 위한 방법 및 조성물 - Google Patents

비효율적 적혈구생성 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20200019261A
KR20200019261A KR1020207004201A KR20207004201A KR20200019261A KR 20200019261 A KR20200019261 A KR 20200019261A KR 1020207004201 A KR1020207004201 A KR 1020207004201A KR 20207004201 A KR20207004201 A KR 20207004201A KR 20200019261 A KR20200019261 A KR 20200019261A
Authority
KR
South Korea
Prior art keywords
actriib
glu
seq
gdf trap
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207004201A
Other languages
English (en)
Korean (ko)
Inventor
자스비르 시헤라
로버트 스콧 피어설
라빈드라 쿠마르
나가 벤카타 사이 라자세하르 수라가니
Original Assignee
악셀레론 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 악셀레론 파마 인코포레이티드 filed Critical 악셀레론 파마 인코포레이티드
Priority to KR1020227017193A priority Critical patent/KR20220075438A/ko
Publication of KR20200019261A publication Critical patent/KR20200019261A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020207004201A 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물 Ceased KR20200019261A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227017193A KR20220075438A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161547932P 2011-10-17 2011-10-17
US61/547,932 2011-10-17
PCT/US2012/060650 WO2013059347A1 (en) 2011-10-17 2012-10-17 Methods and compositions for treating ineffective erythropoiesis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025484A Division KR102079482B1 (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227017193A Division KR20220075438A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20200019261A true KR20200019261A (ko) 2020-02-21

Family

ID=48141315

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020197025484A Active KR102079482B1 (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물
KR1020227017193A Ceased KR20220075438A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물
KR1020207004201A Ceased KR20200019261A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물
KR1020147013325A Ceased KR20140084211A (ko) 2011-10-17 2012-10-17 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020197025484A Active KR102079482B1 (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물
KR1020227017193A Ceased KR20220075438A (ko) 2011-10-17 2012-10-17 비효율적 적혈구생성 치료를 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147013325A Ceased KR20140084211A (ko) 2011-10-17 2012-10-17 효과가 없는 적혈구생성 치료를 위한 방법 및 조성물

Country Status (13)

Country Link
US (4) US20130243743A1 (enExample)
EP (3) EP2797620B1 (enExample)
JP (4) JP6092883B2 (enExample)
KR (4) KR102079482B1 (enExample)
CN (3) CN103987403B (enExample)
AU (4) AU2012326207B2 (enExample)
BR (3) BR122019023166B1 (enExample)
CA (1) CA2852683A1 (enExample)
DK (2) DK3875104T3 (enExample)
EA (2) EA202090053A3 (enExample)
ES (3) ES2741477T3 (enExample)
HK (2) HK1250341A1 (enExample)
WO (1) WO2013059347A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
MX2008006626A (es) 2005-11-23 2008-09-24 Acceleron Pharma Inc Antagonistas de activin-actriia y usos para promover el crecimiento de huesos.
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
WO2008094708A2 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
TWI606062B (zh) 2007-02-09 2017-11-21 艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
WO2009038745A1 (en) 2007-09-18 2009-03-26 Acceleron Pharma Inc. Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20191109T1 (hr) 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
AU2010258931B2 (en) 2009-06-08 2015-04-23 Acceleron Pharma Inc. Methods for increasing thermogenic adipocytes
CN107267520A (zh) 2009-06-12 2017-10-20 阿塞勒隆制药公司 截短的actriib‑fc融合蛋白
ES2869580T3 (es) * 2009-09-09 2021-10-25 Acceleron Pharma Inc Antagonistas de ActRIIB y dosificación y usos de los mismos para tratar obesidad o diabetes tipo 2 regulando el contenido de grasa corporal
CA2781152A1 (en) 2009-11-17 2011-05-26 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (ja) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド Ａｃｔｒｉｉａ結合剤およびその使用
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
ES2884095T3 (es) 2012-11-02 2021-12-10 Celgene Corp Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos
JP2017509647A (ja) * 2014-03-21 2017-04-06 アクセルロン ファーマ， インコーポレイテッド アクチビンｂおよび／またはｇｄｆ１１の阻害によって赤血球レベルを増大させ、無効赤血球生成を処置する方法
US20150361163A1 (en) * 2014-04-18 2015-12-17 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating sickle-cell disease
MA40008A (fr) * 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
AU2015358469B2 (en) * 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
MA41119A (fr) * 2014-12-03 2017-10-10 Acceleron Pharma Inc Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
SG10201913747PA (en) 2015-04-22 2020-03-30 Biogen Ma Inc Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases
TWI814187B (zh) * 2015-05-13 2023-09-01 美商西建公司 使用ACTRII配位體捕捉以治療β-地中海型貧血
JP2018522579A (ja) * 2015-05-20 2018-08-16 セルジーン コーポレイション アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法
WO2017079591A2 (en) * 2015-11-04 2017-05-11 Acceleron Pharma Inc. Methods for increasing red blood cell levels and treating ineffective erythropoiesis
AU2016359695A1 (en) 2015-11-23 2018-06-14 Acceleron Pharma Inc. Methods for treating eye disorders
PL3490582T3 (pl) 2016-07-27 2024-09-23 Acceleron Pharma Inc. Kompozycje do zastosowania w leczeniu mielofibrozy
CN110036025B (zh) * 2016-10-05 2024-03-22 阿塞勒隆制药公司 变体ActRIIB蛋白及其用途
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
WO2018089715A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
PT3638243T (pt) * 2017-06-14 2024-10-31 Celgene Corp Métodos para tratamento da mielofibrose e anemia associadas ao neoplasma mieloproliferativo
JP7258021B2 (ja) 2017-11-09 2023-04-14 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体を含む医薬組成物
IL320014A (en) 2018-01-12 2025-06-01 Keros Therapeutics Inc Activin receptor type iib variants and methods of use thereof
CN112601538B (zh) 2018-05-09 2025-08-19 科乐斯疗法公司 激活素受体iia型变体及其使用方法
JP2022549506A (ja) 2019-09-27 2022-11-25 ディスク・メディシン・インコーポレイテッド 骨髄線維症および関連状態を処置するための方法
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
EP4149548A4 (en) 2020-05-13 2024-05-08 Disc Medicine, Inc. ANTI-HEMOJUVELIN ANTIBODIES (HJV) FOR THE TREATMENT OF MYELOFIBROSIS
US12186370B1 (en) 2020-11-05 2025-01-07 Celgene Corporation ACTRIIB ligand trap compositions and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1265208A (en) 1915-09-07 1918-05-07 Edward C Kahn Liquid-fuel burner.
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5885574A (en) 1994-07-26 1999-03-23 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
CA2359242C (en) 1999-01-21 2009-12-08 Metamorphix, Inc. Growth differentiation factor inhibitors and uses therefor
CA2501936A1 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
US8067562B2 (en) 2005-11-01 2011-11-29 Amgen Inc. Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
US20100028332A1 (en) * 2006-12-18 2010-02-04 Acceleron Pharma Inc. Antagonists of actriib and uses for increasing red blood cell levels
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
US8216997B2 (en) * 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
HRP20191109T1 (hr) * 2008-08-14 2019-09-20 Acceleron Pharma Inc. Gdf klopke za uporabu u liječenju anemije
KR101882521B1 (ko) * 2009-08-13 2018-07-27 악셀레론 파마 인코포레이티드 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용

Also Published As

Publication number Publication date
WO2013059347A1 (en) 2013-04-25
KR102079482B1 (ko) 2020-02-19
HK1252940A1 (zh) 2019-06-06
BR122019023174B1 (pt) 2021-02-23
US20170137791A1 (en) 2017-05-18
BR112014009528B1 (pt) 2020-12-29
EP2797620A4 (en) 2015-05-20
AU2018247262A1 (en) 2018-11-01
EP2797620B1 (en) 2019-04-24
KR20140084211A (ko) 2014-07-04
JP2020186277A (ja) 2020-11-19
JP2014530253A (ja) 2014-11-17
AU2017201580A1 (en) 2017-03-30
JP6796626B2 (ja) 2020-12-09
CN107693776A (zh) 2018-02-16
EA201490809A1 (ru) 2014-09-30
BR112014009528A8 (pt) 2019-12-10
EP3875104A1 (en) 2021-09-08
HK1203413A1 (en) 2015-10-30
CN107837390A (zh) 2018-03-27
JP6383821B2 (ja) 2018-08-29
JP2017101060A (ja) 2017-06-08
EP2797620A1 (en) 2014-11-05
KR20190105113A (ko) 2019-09-11
DK3875104T3 (da) 2025-02-03
AU2017201580B2 (en) 2018-07-12
JP2018165287A (ja) 2018-10-25
DK3520805T3 (da) 2021-04-19
KR20220075438A (ko) 2022-06-08
CA2852683A1 (en) 2013-04-25
BR122019023166B1 (pt) 2021-02-23
AU2020286229A1 (en) 2021-01-07
US20210207107A1 (en) 2021-07-08
AU2012326207A1 (en) 2014-05-15
CN103987403B (zh) 2017-12-01
BR112014009528A2 (pt) 2017-05-09
EP3875104B1 (en) 2025-01-22
HK1250341A1 (zh) 2018-12-14
US20130243743A1 (en) 2013-09-19
JP6092883B2 (ja) 2017-03-08
ES2869168T3 (es) 2021-10-25
EA202090053A2 (ru) 2020-04-30
EA034563B1 (ru) 2020-02-20
AU2018247262B2 (en) 2020-12-24
EP3520805A1 (en) 2019-08-07
AU2012326207B2 (en) 2016-12-15
CN103987403A (zh) 2014-08-13
ES2741477T3 (es) 2020-02-11
EA202090053A3 (ru) 2020-06-30
US20170327800A1 (en) 2017-11-16
ES3010483T3 (en) 2025-04-03
EP3520805B1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
KR102079482B1 (ko) 비효율적 적혈구생성 치료를 위한 방법 및 조성물
JP7329573B2 (ja) 赤血球レベルを高めるためのｇｄｆトラップの使用
CN102655872B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
RU2814047C2 (ru) Комбинированное применение ловушек gdf и активаторов рецепторов эритропоэтина для повышения содержания эритроцитов
HK40057480A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK40057480B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
HK40053188A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1224199B (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1224576A1 (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
HK1224576B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
HK1223818B (zh) Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平
HK40011608B (en) Compositions for treating myelofibrosis
HK40011608A (en) Compositions for treating myelofibrosis
HK1203413B (en) Compositions for treating iron overload in thalassemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200212

Application number text: 1020197025484

Filing date: 20190830

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200417

Patent event code: PE09021S01D

AMND Amendment
E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20210109

Patent event code: PE09021S02D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211112

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210109

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20200417

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20211112

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210709

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201016

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20220219

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220211

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20211112

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20210709

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20210109

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201016

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20200417

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220523

Application number text: 1020197025484

Filing date: 20190830

PJ0201 Trial against decision of rejection

Patent event date: 20220523

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20220219

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20211112

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20220707

Appeal identifier: 2022101001188

Request date: 20220523

PJ0801 Rejection of trial

Patent event date: 20220707

Patent event code: PJ08011S01D

Comment text: Decision on Dismissal of Request for Trial (Dismissal of Decision)

Decision date: 20220707

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2022101001188

Request date: 20220523